

Board Meeting in Public

Tuesday, 02 December 2025

Title of Paper	Governance Update	Agenda No.	5.1
Nature of Paper	<input checked="" type="checkbox"/> Official	<input type="checkbox"/> Official Sensitive	
Author(s)	Silena Dominy, Company Secretary		
Lead Executive	Helen Gillan, Director of Quality and Governance		
Non-Executive Director Sponsor	Peter Wyman, Chair		
Presenter(s) at Meeting	Silena Dominy, Company Secretary		
Presented for	<input type="checkbox"/> Approval <input checked="" type="checkbox"/> Information <input type="checkbox"/> Assurance <input checked="" type="checkbox"/> Update		
Is there a plan to communicate this to the organisation?	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No <input type="checkbox"/> Yet to be determined Published in public Board pack		
Executive Summary			
This report provides the Board with an update on corporate governance matters in NHS Blood and Transplant (NHSBT).			
Previously Considered by			
N/A			
Recommendation			
The Board is asked to note the report.			
Risk(s) identified (Link to Board Assurance Framework Risks)			
BAF P11 Corporate Governance "There is a risk that the Board does not have full oversight of significant risk caused by ineffective systems or their application resulting in uninformed decision-making, a requirement for emergency management, sub-optimal outcomes and reputational damage" The frequent review of governance arrangements ensures continuous improvement and oversight reduces the likelihood of the Board not fulfilling its duties, or stepping outside of its powers, therefore strengthens governance.			
Strategic Objective(s) this paper relates to:			
<input checked="" type="checkbox"/> Collaborate with partners <input checked="" type="checkbox"/> Invest in people and culture <input type="checkbox"/> Drive innovation <input checked="" type="checkbox"/> Modernise our operations <input type="checkbox"/> Grow and diversify our donor base			
Appendices:			

1. Background

This report provides the Board with an update on Corporate Governance matters in NHSBT.

2. Board Level Policies

No Board Level Policies are presented for approval at this meeting, however the Risk Management Framework is presented for noting.

3. Board Effectiveness Review

On an annual basis the Board completes an effectiveness review. On a triennial basis this is externally facilitated, as was the case for 2024-25 when BDO LLP completed a review. In the intervening years reviews are undertaken internally. Questionnaires will be circulated to Directors for completion during December 2025, following which feedback will be analysed and a report on the findings and any recommendations to improve the effectiveness of the Board will be presented at the February 2026 meeting of the Board.

4. Board Skills, Capabilities and Diversity

The assessment of Board skills, capabilities and diversity has been completed following completion of self-assessments by directors. The findings are presented at agenda item 5.1.1.

5. Stakeholder Engagement

Information in relation to engagements of the Chair and Chief Executive with stakeholders and DHSC since the last meeting is included in the Review Room for this meeting.